A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics.

The tumor microenvironment provides unique challenges for the delivery of chemotherapeutic agents in doses that are effective while ensuring minimal systemic toxicity. The primary limitation of current therapeutics is a lack of specificity in delivery, as they target healthy and cancerous cells alike. The development of nanoscale carriers capable of delivering cancer therapies has the potential to overcome both systemic and tumor barriers and provide specific, targeted delivery. This review seeks to provide an overview of available nanoscale drug carriers by exploring the wide variety of developed nanostructures and the most commonly used moieties for targeted delivery. Additionally, the use of nanoscale carriers will be motivated by examining tumor physiology and the specific barriers present within both the tumor microenvironment and systemic delivery.

[1]  William B. Liechty,et al.  Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[3]  E. Rowinsky.  The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. , 1997, Annual review of medicine.

[4]  D. Lasič.  Novel applications of liposomes. , 1998, Trends in biotechnology.

[5]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[6]  Xiaoling Fang,et al.  Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. , 2011, Biomaterials.

[7]  A. Harris,et al.  New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. , 1998, The cancer journal from Scientific American.

[8]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[9]  Bengt Rippe,et al.  Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability. , 2005, American journal of physiology. Renal physiology.

[10]  S. Mitragotri,et al.  Making polymeric micro- and nanoparticles of complex shapes , 2007, Proceedings of the National Academy of Sciences.

[11]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[12]  Xu Wang,et al.  Application of Nanotechnology in Cancer Therapy and Imaging , 2008, CA: a cancer journal for clinicians.

[13]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[14]  Shu Chien,et al.  Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , 2003 .

[15]  Nicholas A Peppas,et al.  Expert opinion: Responsive polymer nanoparticles in cancer therapy. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[16]  Tae Gwan Park,et al.  Folate receptor targeted biodegradable polymeric doxorubicin micelles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[17]  R. Gurny,et al.  Biodegradable nanoparticles for direct or two-step tumor immunotargeting. , 2006, Bioconjugate chemistry.

[18]  P. Couvreur,et al.  Design of folic acid-conjugated nanoparticles for drug targeting. , 2000, Journal of pharmaceutical sciences.

[19]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[20]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[21]  Joseph M DeSimone,et al.  Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. , 2005, Journal of the American Chemical Society.

[22]  Philip S Low,et al.  Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.

[23]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[24]  F. Caruso,et al.  Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules. , 2012, ACS nano.

[25]  G. Hughes,et al.  Nanostructure-mediated drug delivery. , 2005, Disease-a-month : DM.

[26]  C. Lok,et al.  The transferrin receptor: role in health and disease. , 1999, The international journal of biochemistry & cell biology.

[27]  G. Palade,et al.  Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.

[28]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[29]  H. Maeda,et al.  Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. , 1998, Cancer research.

[30]  Nicholas A Peppas,et al.  Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. , 2011, Accounts of chemical research.

[31]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[32]  Nicholas A Peppas,et al.  pH-Responsive Hydrogels with Dispersed Hydrophobic Nanoparticles for the Delivery of Hydrophobic Therapeutic Agents. , 2012, Polymer international.

[33]  S. Sahoo,et al.  Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.

[34]  E. Frenkel,et al.  Nanoparticles for drug delivery in cancer treatment. , 2008, Urologic oncology.

[35]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[36]  J. Szostak,et al.  In vitro selection of functional nucleic acids. , 1999, Annual review of biochemistry.

[37]  Warren C W Chan,et al.  Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. , 2007, Nano letters.

[38]  G. Hughes.  Nanostructure-mediated drug delivery. , 2005, Nanomedicine : nanotechnology, biology, and medicine.

[39]  S. Sahoo,et al.  Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. , 2005, Molecular pharmaceutics.

[40]  K. Hori,et al.  Characterization of Heterogeneous Distribution of Tumor Blood Flow in the Rat , 1991, Japanese journal of cancer research : Gann.

[41]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[42]  Hua Ai,et al.  cRGD-functionalized polymer micelles for targeted doxorubicin delivery. , 2004, Angewandte Chemie.

[43]  M. Dewhirst,et al.  Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. , 2006, Journal of the National Cancer Institute.

[44]  M. During,et al.  Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules , 2006 .

[45]  Robert Langer,et al.  Targeted nanoparticles for cancer therapy , 2007 .

[46]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[47]  Li Shi,et al.  Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers , 2010, Expert opinion on drug delivery.

[48]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[49]  Nicholas A Peppas,et al.  Micro- and nanotechnologies for intelligent and responsive biomaterial-based medical systems. , 2009, Advanced drug delivery reviews.

[50]  Kazunori Kataoka,et al.  Block copolymer micelles as long-circulating drug vehicles , 1995 .

[51]  Seymour,et al.  Control of tumour vascular permeability. , 1998, Advanced drug delivery reviews.

[52]  Rakesh K Jain,et al.  Delivery of molecular and cellular medicine to solid tumors. , 1997, Advanced drug delivery reviews.

[53]  Donald L Weaver,et al.  Selection of tumor-binding ligands in cancer patients with phage display libraries. , 2006, Cancer research.

[54]  R. Weiss.  The anthracyclines: will we ever find a better doxorubicin? , 1992, Seminars in oncology.

[55]  Louis M Weiner,et al.  New approaches to antibody therapy , 2000, Oncogene.

[56]  R. Duncan.  The dawning era of polymer therapeutics , 2003, Nature Reviews Drug Discovery.

[57]  Laurence H. Hurley,et al.  DNA and its associated processes as targets for cancer therapy , 2002, Nature Reviews Cancer.

[58]  N. Goldstein,et al.  Identification of cancer targets and therapeutics using phage display. , 2006, Current opinion in drug discovery & development.

[59]  Ick Chan Kwon,et al.  New Generation of Multifunctional Nanoparticles for Cancer Imaging and Therapy , 2009 .

[60]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[61]  Thommey P. Thomas,et al.  PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. , 2006, Biomacromolecules.

[62]  Rui Huang,et al.  Swelling behavior of nanoscale, shape- and size-specific, hydrogel particles fabricated using imprint lithography , 2011 .

[63]  H. Bier,et al.  Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. , 1997, Anticancer research.

[64]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[65]  L. Brannon-Peppas,et al.  Nanoparticle and targeted systems for cancer therapy. , 2004, Advanced drug delivery reviews.

[66]  J. Mendelsohn.  Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[67]  Buddy D. Ratner,et al.  Biomaterials Science: An Introduction to Materials in Medicine , 1996 .

[68]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[69]  S. Davis,et al.  Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan‐stimulated rats , 1993, Journal of leukocyte biology.

[70]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[71]  R K Jain,et al.  Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. , 1996, The American journal of pathology.

[72]  Li Shi,et al.  Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[73]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[74]  T. Boulikas,et al.  Cisplatin and platinum drugs at the molecular level. (Review). , 2003, Oncology reports.

[75]  Hong-Zhuan Chen,et al.  In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[76]  Tetsurou Yamamoto,et al.  Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor Tissue , 1988, Japanese journal of cancer research : Gann.

[77]  John Samuel,et al.  Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. , 2002, Advanced drug delivery reviews.

[78]  Nicholas A Peppas,et al.  Targeted Nanodelivery of Drugs and Diagnostics. , 2010, Nano today.